>, Pharma & lifesciences>Yondelis v Yloelis: General Court upholds opposition for medicinal product names for use and not for use in oncology (Allen & Overy)

Yondelis v Yloelis: General Court upholds opposition for medicinal product names for use and not for use in oncology (Allen & Overy)

On 16 May 2017, the General Court handed down its decision in Alfa Wasserman SpA (AW) v EUIPO, Pharma Mar intervening (Case T- 85/15).  The decision follows the opposition by Pharma Mar (Pharma), owner of the EU trade mark YONDELIS for pharmaceutical and veterinary products and preparations for use in oncology, against the application by Alfa Wassermann (Alfa) for the mark YLOELIS for pharmaceutical products and medicines not for use in oncology.

The Opposition Division upheld Pharma’s opposition, finding a likelihood of confusion between the marks.  This decision was upheld by the First Board of Appeal.

Read the full article here

2017-05-25T12:54:55+00:00 25 mei 2017|Categories: Intellectuele rechten - Pharma & lifesciences|Tags: , |